Liver Int:肝移植受者结直肠癌的发病率和预后:8115例患者的国家多中心分析

2018-08-23 MedSci MedSci原创

肝移植并不能增加结直肠癌的发病风险。原发性硬化性胆管炎/溃疡性结肠炎肝移植患者发生结直肠癌的风险明显高于一般人群,在诊断时有较高比例,的病人处于疾病晚期,病人的存活率降低。

研究背景:肝移植术后,新发恶性肿瘤是患者死亡的主要原因之一。目前尚不清楚肝移植受者是否会增加直肠癌患病的风险,以及是否会对生存率产生负面影响。

研究方法:此研究为多中心队列回顾性研究,将1990年1月1日(st)至2010年12月31日(st)间接受肝移植的8115例成人患者的直肠癌发病率与普通人群发病率进行比较。

研究结果:在肝移植5.6年(中位时间)后,52例(0.6%)患者发生结直肠癌,疾病主要为2级(76.9%)和T3期(50%)。整个肝移植人群中结直肠癌的发病率与英国普通人群相似(SIR 0.92),但在受原发性硬化性胆管炎/溃疡性结肠炎影响的患者组中,发病率明显增高(SIR 7.0)。1、5、10年结直肠癌生存率分别为71%、48%和31%,大多数结直肠癌患者死于特定的癌症。

研究结论:肝移植并不能增加结直肠癌的发病风险。原发性硬化性胆管炎/溃疡性结肠炎肝移植患者发生结直肠癌的风险明显高于一般人群,在诊断时有较高比例,的病人处于疾病晚期,病人的存活率降低。

原始出处:

Rompianesi G, Ravikumar R, Jose S, et al. Incidence and outcome of colorectal cancer in liver transplant recipients: A national, multicentre analysis on 8115 patients. Liver Int, 2018,Aug 20. doi: 10.1111/liv.13947.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1823485, encodeId=9b541823485fd, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Tue Mar 05 13:28:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903958, encodeId=bc821903958e5, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Fri Aug 02 01:28:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453149, encodeId=fafb1453149f6, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sat Aug 25 10:28:00 CST 2018, time=2018-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340414, encodeId=b8d63404149d, content=不错的文章值得拥有哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Thu Aug 23 22:25:04 CST 2018, time=2018-08-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1823485, encodeId=9b541823485fd, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Tue Mar 05 13:28:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903958, encodeId=bc821903958e5, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Fri Aug 02 01:28:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453149, encodeId=fafb1453149f6, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sat Aug 25 10:28:00 CST 2018, time=2018-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340414, encodeId=b8d63404149d, content=不错的文章值得拥有哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Thu Aug 23 22:25:04 CST 2018, time=2018-08-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1823485, encodeId=9b541823485fd, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Tue Mar 05 13:28:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903958, encodeId=bc821903958e5, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Fri Aug 02 01:28:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453149, encodeId=fafb1453149f6, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sat Aug 25 10:28:00 CST 2018, time=2018-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340414, encodeId=b8d63404149d, content=不错的文章值得拥有哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Thu Aug 23 22:25:04 CST 2018, time=2018-08-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1823485, encodeId=9b541823485fd, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Tue Mar 05 13:28:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903958, encodeId=bc821903958e5, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Fri Aug 02 01:28:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453149, encodeId=fafb1453149f6, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sat Aug 25 10:28:00 CST 2018, time=2018-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340414, encodeId=b8d63404149d, content=不错的文章值得拥有哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Thu Aug 23 22:25:04 CST 2018, time=2018-08-23, status=1, ipAttribution=)]
    2018-08-23 1e1b8538m79(暂无匿称)

    不错的文章值得拥有哦

    0

相关资讯

Transpl P:吸入麻醉药对肝移植患者早期临床结局的影响

很少有研究报道吸入麻醉药对肝移植术后缺血再灌注损伤(IRI)中的影响。本研究拟对2001和2015之间所有肝移植(LT)器官受者和器官捐赠者的数据进行单中心回顾性分析,比较吸入性麻醉药对早期肝移植患者IRI的影响。

Liver Int:DAA联合治疗肝移植后的丙肝复发是非常有效和耐受的

DAA联合治疗丙肝复发是非常有效和耐受的。长期数据显示,病毒根除是持久的,但不一定转化为有益的长期临床结果。

Clin Gastroenterol H:在肝移植候选者中,非酒精性脂肪性肝炎是肝细胞癌病因中增长快速的

乙肝和丙肝是肝细胞癌(HCC)的主要病因,但最近非酒精性脂肪性肝炎(NASH)成为了肝癌的重要病因。本研究的目的是评估美国肝移植(LT)候选人中肝细胞癌的病因。

J Hepatol:直接抗病毒药物提高了肝移植后患者的早期生存率,并引起肝移植等待名单的显著变化

DAAs的高疗效与肝移植等待名单的组成发生显著变化有关,更重要的是,可以提高移植后的存活率。

Transplantation:利妥昔单抗单药且无额外脱敏治疗用于ABO血型不合活体供肝肝移植的可行性分析

近年来,在肝移植领域,随着各种防治抗体介导的排斥反应(AMR)策略的临床运用,如利妥昔单抗等免疫抑制剂、血浆置换(PP)、移植物局部灌注(LI)与脾切除等,使得ABO血型不合肝移植(ABO-i LT)成功案例的报道逐渐增多。

英国科学家发现了肝衰竭的潜在新疗法:TGF-β抑制剂

研究人员发现抗癌药物TGF-β的抑制剂可以促进肝脏在严重损伤后的再生,这种新的治疗方法可能帮助肝损伤患者免于肝脏移植的痛苦。